DIAGNOSTICOS DA AMÉRICA S.A. Financials Diagnosticos da América S.A.
Equities
DASA3
BRDASAACNOR1
Healthcare Facilities & Services
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.6 BRL | +5.26% |
|
+8.49% | -52.18% |
| Mar. 28 | Transcript : Diagnósticos da América S.A., Q4 2023 Earnings Call, Mar 28, 2024 | |
| Mar. 27 | Diagnósticos da América S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 34,851 | 18,485 | 7,686 | 7,186 | 3,436 | - | - |
| Enterprise Value (EV) 1 | 34,851 | 26,409 | 7,686 | 16,167 | 15,578 | 13,886 | 13,671 |
| P/E ratio | - | -90.8 x | -19.8 x | -6.16 x | 30.7 x | 5.41 x | - |
| Yield | - | 0.89% | - | - | 0.65% | 3.19% | - |
| Capitalization / Revenue | 4.95 x | 1.77 x | 0.59 x | 0.46 x | 0.22 x | 0.21 x | 0.19 x |
| EV / Revenue | 4.95 x | 2.53 x | 0.59 x | 1.04 x | 1 x | 0.83 x | 0.77 x |
| EV / EBITDA | - | 20.6 x | 3.54 x | 6.91 x | 5.46 x | 4.36 x | 3.87 x |
| EV / FCF | - | -7.23 x | - | -9.11 x | 34.8 x | 14.6 x | 11.2 x |
| FCF Yield | - | -13.8% | - | -11% | 2.87% | 6.83% | 8.95% |
| Price to Book | - | 2.51 x | - | 0.99 x | 0.44 x | 0.44 x | - |
| Nbr of stocks (in thousands) | 480,705 | 547,872 | 559,827 | 746,960 | 747,048 | - | - |
| Reference price 2 | 72.50 | 33.74 | 13.73 | 9.620 | 4.600 | 4.600 | 4.600 |
| Announcement Date | 3/7/21 | 3/28/22 | 3/28/23 | 3/28/24 | - | - | - |
1BRL in Million2BRL
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 7,039 | 10,419 | 13,129 | 15,557 | 15,639 | 16,737 | 17,759 |
| EBITDA 1 | - | 1,282 | 2,168 | 2,339 | 2,855 | 3,183 | 3,533 |
| EBIT 1 | - | 351.7 | 1,102 | 913.3 | 1,523 | 1,900 | 2,091 |
| Operating Margin | - | 3.38% | 8.39% | 5.87% | 9.74% | 11.35% | 11.77% |
| Earnings before Tax (EBT) 1 | - | -374.2 | -578.8 | -996 | 114.8 | 765 | - |
| Net income 1 | -150.8 | -226.6 | -386.9 | -1,130 | 65.73 | 586.2 | 666.5 |
| Net margin | -2.14% | -2.17% | -2.95% | -7.26% | 0.42% | 3.5% | 3.75% |
| EPS 2 | - | -0.3715 | -0.6932 | -1.561 | 0.1500 | 0.8500 | - |
| Free Cash Flow 1 | - | -3,654 | - | -1,775 | 447 | 949 | 1,224 |
| FCF margin | - | -35.07% | - | -11.41% | 2.86% | 5.67% | 6.89% |
| FCF Conversion (EBITDA) | - | - | - | - | 15.66% | 29.81% | 34.64% |
| FCF Conversion (Net income) | - | - | - | - | 680.05% | 161.9% | 183.65% |
| Dividend per Share 2 | - | 0.3012 | - | - | 0.0300 | 0.1467 | - |
| Announcement Date | 3/7/21 | 3/28/22 | 3/28/23 | 3/28/24 | - | - | - |
1BRL in Million2BRL
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,721 | 2,673 | 3,136 | 3,288 | 3,425 | 3,279 | 3,534 | 3,631 | 3,769 | 3,777 | 3,731 | 3,903 | 4,046 |
| EBITDA 1 | 543.7 | 222.9 | 560.5 | 512.3 | 607.3 | 457.6 | 615.7 | 526.1 | 660.8 | 438 | 683.9 | - | - |
| EBIT 1 | 299 | -39.21 | 288.4 | 227.3 | 307.9 | 208 | 306 | 215.4 | 331 | 60.98 | 447.5 | 404.4 | 511.7 |
| Operating Margin | 10.99% | -1.47% | 9.2% | 6.91% | 8.99% | 6.34% | 8.66% | 5.93% | 8.78% | 1.61% | 11.99% | 10.36% | 12.65% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income 1 | 73.6 | -167.1 | 37.11 | -120.1 | -89.36 | -214.6 | -166 | -282.1 | -180.5 | -495 | -30 | - | - |
| Net margin | 2.7% | -6.25% | 1.18% | -3.65% | -2.61% | -6.54% | -4.7% | -7.77% | -4.79% | -13.11% | -0.8% | - | - |
| EPS 2 | 0.1281 | -0.2630 | 0.0636 | -0.2145 | -0.1592 | -0.3853 | -0.3019 | -0.3803 | - | - | 0.0500 | 0.0200 | 0.1100 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/12/21 | 3/28/22 | 5/12/22 | 8/11/22 | 11/14/22 | 3/28/23 | 5/12/23 | 8/10/23 | 11/9/23 | 3/28/24 | - | - | - |
1BRL in Million2BRL
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 7,924 | - | 8,981 | 12,141 | 10,450 | 10,235 |
| Net Cash position 1 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | 6.183 x | - | 3.84 x | 4.253 x | 3.282 x | 2.897 x |
| Free Cash Flow 1 | - | -3,654 | - | -1,775 | 447 | 949 | 1,224 |
| ROE (net income / shareholders' equity) | - | -4.09% | - | -16.2% | 2.4% | 5.41% | 7.04% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 13.50 | - | 9.740 | 10.50 | 10.50 | - |
| Cash Flow per Share 2 | - | 2.320 | - | -1.290 | 1.700 | - | - |
| Capex 1 | - | 4,952 | - | 727 | 841 | 774 | 860 |
| Capex / Sales | - | 47.53% | - | 4.67% | 5.38% | 4.62% | 4.84% |
| Announcement Date | 3/7/21 | 3/28/22 | 3/28/23 | 3/28/24 | - | - | - |
1BRL in Million2BRL
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
4.6
BRL
Average target price
9.889
BRL
Spread / Average Target
+114.98%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -52.18% | 670M | |
| -14.92% | 84.68B | |
| +13.30% | 81.12B | |
| +10.92% | 29.4B | |
| -12.71% | 16.73B | |
| -3.06% | 16.36B | |
| -2.63% | 14.92B | |
| -31.75% | 11.77B | |
| -1.42% | 11.72B | |
| +27.44% | 11.71B |
- Stock Market
- Equities
- DASA3 Stock
- Financials Diagnosticos da América S.A.
